NVO files an NDA with the FDA for once-weekly CagriSema, a combo obesity injection showing superior weight loss in obese patients in phase III studies.
The perception of GLP-1s — and the people who use them — is getting better, but work still must be done to avoid stigma.
Research collected by University of Guelph post doctoral scholar Megan Ross as part of her recent PhD work from the Atlantic ...
The filing comes as Novo fights tooth-and-nail with rival Lilly to regain its footing at the top of the weight loss market.
Novo Nordisk filed an FDA application for weekly CagriSema after trials showed up to 22.7% weight loss versus placebo.
Retatrutide treatment resulted in significant improvements in WOMAC pain scores and body weight compared with placebo in the TRIUMPH-4 trial.
TipRanks on MSN
AstraZeneca’s AZD5004 obesity trial edges forward, raising new questions for investors
AstraZeneca ($AZN) announced an update on their ongoing clinical study. Study Overview AstraZeneca is running a Phase IIb study called “A Phase ...
More GLP-1s aim to enter US market as Novo Nordisk, Eli Lilly, and Pfizer advance obesity treatments with FDA filings and trials.
A major review in Frontiers in Science highlights how tackling unsustainable food systems—reflected by our changing food ...
Eli Lilly (LLY) stock is in focus as the company posts late-stage trial data to indicate that its obesity pill orforglipron ...
A major review in Frontiers in Science highlights how tackling unsustainable food systems—reflected by our changing food ...
This study also reminds us that vitamin C is good for more than just avoiding scurvy. It helps the body heal, protects ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback